Shenyang Sunshine Pharmaceutical Co., LTD.
Quick facts
Marketed products
- EPIAO® · Other
- TPO · Hematology
TPO is a thrombopoietin receptor agonist that stimulates platelet production by binding to and activating the thrombopoietin receptor on hematopoietic stem cells.
Phase 3 pipeline
- PD-1 Inhibitor + Chemotherapy · Oncology
This combination therapy blocks PD-1 immune checkpoints to restore anti-tumor immunity while chemotherapy directly kills cancer cells.
Phase 2 pipeline
Phase 1 pipeline
- [14C]SSS17
- HBT-708
- Humanized TNFα monoclonal antibody
- PEGylated recombinant candida urate oxidase
- Recombinant erythropoietin stimulating protein
- SPGL008
- SSGJ-612
- SSGJ-709
- SSS11
- SSS39
- SSS55
- SSS59
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: